Detalles de la búsqueda
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med
; 21(3): e1004360, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502656
2.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis
; 2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37795976
3.
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
N Engl J Med
; 381(25): 2429-2439, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31661198
4.
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Clin Infect Dis
; 72(1): 50-60, 2021 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31900486
5.
Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
N Engl J Med
; 379(17): 1621-1634, 2018 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280651
6.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med
; 17(2): e1003038, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32092060
7.
Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults.
J Viral Hepat
; 26(9): 1066-1075, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31087382
8.
A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. Reply.
N Engl J Med
; 382(16): 1577, 2020 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32294369
9.
Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence.
J Infect Dis
; 205(8): 1214-9, 2012 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22383676
10.
Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
Southeast Asian J Trop Med Public Health
; 42(1): 138-47, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21323176
11.
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Clin Infect Dis
; 51(6): 656-62, 2010 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20704493
12.
Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life.
BMC Infect Dis
; 10: 9, 2010 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20078876
13.
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
Hum Vaccin
; 6(7): 554-61, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20448468
14.
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
Vaccine
; 38(7): 1678-1689, 2020 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932137
15.
Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
Medicine (Baltimore)
; 97(45): e13120, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30407329
16.
Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.
Hum Vaccin Immunother
; 13(5): 972-980, 2017 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28281907
17.
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
Hum Vaccin Immunother
; 13(1): 120-127, 2017 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27629913
18.
Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
Hum Vaccin Immunother
; 13(3): 588-598, 2017 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27768515
19.
Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine.
Vaccine
; 34(24): 2745-9, 2016 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27095043
20.
Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
Hum Vaccin Immunother
; 12(11): 2916-2920, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27653771